These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 30368548

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen.
    Thorsted A, Kristoffersson AN, Maarbjerg SF, Schrøder H, Wang M, Brock B, Nielsen EI, Friberg LE.
    J Antimicrob Chemother; 2019 Oct 01; 74(10):2984-2993. PubMed ID: 31273375
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation.
    Kim YK, Kim HS, Park S, Kim HI, Lee SH, Lee DH.
    J Antimicrob Chemother; 2022 Apr 27; 77(5):1353-1364. PubMed ID: 35224630
    [Abstract] [Full Text] [Related]

  • 8. Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
    Kanji S, Roberts JA, Xie J, Alobaid A, Zelenitsky S, Hiremath S, Zhang G, Watpool I, Porteous R, Patel R.
    Ann Pharmacother; 2018 Oct 27; 52(10):965-973. PubMed ID: 29730948
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Population pharmacokinetic analysis of piperacillin in burn patients.
    Jeon S, Han S, Lee J, Hong T, Paek J, Woo H, Yim DS.
    Antimicrob Agents Chemother; 2014 Jul 27; 58(7):3744-51. PubMed ID: 24752260
    [Abstract] [Full Text] [Related]

  • 12. Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?
    Öbrink-Hansen K, Juul RV, Storgaard M, Thomsen MK, Hardlei TF, Brock B, Kreilgaard M, Gjedsted J.
    Antimicrob Agents Chemother; 2015 Nov 27; 59(11):7018-26. PubMed ID: 26349823
    [Abstract] [Full Text] [Related]

  • 13. Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study.
    Zander J, Döbbeler G, Nagel D, Maier B, Scharf C, Huseyn-Zada M, Jung J, Frey L, Vogeser M, Zoller M.
    Crit Care; 2016 Apr 04; 20():79. PubMed ID: 27039986
    [Abstract] [Full Text] [Related]

  • 14. Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study.
    Benech N, Dumitrescu O, Conrad A, Balsat M, Paubelle E, Ducastelle-Lepretre S, Labussière-Wallet H, Salles G, Cohen S, Goutelle S, Ader F, Lyon HEMINF Study Group.
    J Antimicrob Chemother; 2019 Sep 01; 74(9):2676-2680. PubMed ID: 31219562
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of pharmacokinetic/pharmacodynamic and clinical outcomes with 6-hourly empiric piperacillin-tazobactam dosing in hematological malignancy patients with febrile neutropenia.
    Weber N, Jackson K, McWhinney B, Ungerer J, Kennedy G, Lipman J, Roberts JA.
    J Infect Chemother; 2019 Jul 01; 25(7):503-508. PubMed ID: 30879981
    [Abstract] [Full Text] [Related]

  • 16. Emergence of antimicrobial resistance to piperacillin/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study.
    Dhaese SAM, De Kezel M, Callant M, Boelens J, De Bus L, Depuydt P, De Waele JJ.
    J Crit Care; 2018 Oct 01; 47():164-168. PubMed ID: 30005302
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
    Sturm AW, Allen N, Rafferty KD, Fish DN, Toschlog E, Newell M, Waibel B.
    Pharmacotherapy; 2014 Jan 01; 34(1):28-35. PubMed ID: 23864417
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
    Richter DC, Frey O, Röhr A, Roberts JA, Köberer A, Fuchs T, Papadimas N, Heinzel-Gutenbrunner M, Brenner T, Lichtenstern C, Weigand MA, Brinkmann A.
    Infection; 2019 Dec 01; 47(6):1001-1011. PubMed ID: 31473974
    [Abstract] [Full Text] [Related]

  • 19. Effect of albumin substitution on pharmacokinetics of piperacillin/tazobactam in patients with severe burn injury admitted to the ICU.
    Wulkersdorfer B, Bergmann F, Amann L, Fochtmann-Frana A, Al Jalali V, Kurdina E, Lackner E, Wicha SG, Dorn C, Schäfer B, Ihra G, Rath T, Radtke C, Zeitlinger M.
    J Antimicrob Chemother; 2024 Feb 01; 79(2):262-270. PubMed ID: 38069908
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.